prikaz prve stranice dokumenta Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
  Preuzmi
PDF 1.17 MB
Znanstveni rad - Izvorni znanstveni rad
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Blood Cancer Journal, 12 (2022), 4; 71. https://doi.org/10.1038/s41408-022-00668-8
Pratz, Keith W.; Panayiotidis, Panayiotis; Recher, Christian; Wei, Xudong; Jonas, Brian A.; Montesinos, Pau; Ivanov, Vladimir; Schuh, Andre C.; DiNardo, Courtney D.; Novak, Jan; Pejša, Vlatko; Stevens, Don; Yeh, Su-Peng; Kim, Inho; Turgut, Mehmet; Fracchiolla, Nicola; Yamamoto, Kazuhito; Ofran, Yishai; Wei, Andrew H.; Bui, Cat N.; Benjamin, Katy; Kamalakar, Rajesh; Potluri, Jalaja; Mendes, Wellington; Devine, Jacob; Fiedler, Walter Više autora...

Citirajte ovaj rad

Pratz, K. W., Panayiotidis, P., Recher, C., Wei, X., Jonas, B. A., Montesinos, P. ... Fiedler, W. (2022). Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer Journal, 12. (4). doi: 10.1038/s41408-022-00668-8

Pratz, Keith W., et al. "Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia." Blood Cancer Journal, vol. 12, br. 4, 2022. https://doi.org/10.1038/s41408-022-00668-8

Pratz, Keith W., Panayiotis Panayiotidis, Christian Recher, Xudong Wei, Brian A. Jonas, Pau Montesinos, Vladimir Ivanov, et al. "Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia." Blood Cancer Journal 12, br. 4 (2022). https://doi.org/10.1038/s41408-022-00668-8

Pratz, K. W., et al. (2022) 'Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia', Blood Cancer Journal, 12(4). doi: 10.1038/s41408-022-00668-8

Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, i sur.. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer Journal [Internet]. 20.04.2022. [pristupljeno 08.11.2024.];12(4). doi: 10.1038/s41408-022-00668-8

K. W. Pratz, et al., "Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia", Blood Cancer Journal, vol. 12, br. 4, Travanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:795165. [Citirano: 08.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:795165
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
AutorKeith W. Pratz
AutorPanayiotis Panayiotidis
AutorChristian Recher
AutorXudong Wei
AutorBrian A. Jonas
AutorPau Montesinos
AutorVladimir Ivanov
AutorAndre C. Schuh
AutorCourtney D. DiNardo
AutorJan Novak
AutorVlatko Pejša
AutorDon Stevens
AutorSu-Peng Yeh
AutorInho Kim
AutorMehmet Turgut
AutorNicola Fracchiolla
AutorKazuhito Yamamoto
AutorYishai Ofran
AutorAndrew H. Wei
AutorCat N. Bui
AutorKaty Benjamin
AutorRajesh Kamalakar
AutorJalaja Potluri
AutorWellington Mendes
AutorJacob Devine
AutorWalter Fiedler
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBlood Cancer Journal
Brojčani podacivol. 12, br. 4, 71
e-ISSN2044-5385
DOIhttps://doi.org/10.1038/s41408-022-00668-8
URN:NBNurn:nbn:hr:105:795165
Datum objave publikacije2022-04-20
URL dokumentahttps://www.nature.com/articles/s41408-022-00668-8
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-12-15 10:58:20